GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.53 | 33.37 | 34.38 | 27.50 | 32.78 |
| CEPS(Rs) | 35.04 | 52.46 | 50.10 | 42.28 | 44.33 |
| DPS(Rs) | 2.50 | 2.50 | 2.50 | 2.50 | 2.00 |
| Book NAV/Share(Rs) | 335.13 | 321.45 | 249.60 | 214.65 | 198.27 |
| Tax Rate(%) | 56.54 | 31.06 | 29.83 | 29.20 | 28.88 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 7.69 | 8.35 | 8.26 | 15.96 | 16.07 |
| EBIT Margin(%) | 4.11 | 6.26 | 6.88 | 13.85 | 16.58 |
| Pre Tax Margin(%) | 2.93 | 5.18 | 5.48 | 10.30 | 13.18 |
| PAT Margin (%) | 1.27 | 3.57 | 3.84 | 7.29 | 9.38 |
| Cash Profit Margin (%) | 3.34 | 5.32 | 5.60 | 11.21 | 12.68 |
| Performance Ratios | |||||
| ROA(%) | 2.29 | 6.74 | 7.11 | 6.17 | 7.98 |
| ROE(%) | 4.07 | 12.33 | 14.81 | 13.32 | 17.21 |
| ROCE(%) | 9.17 | 14.19 | 15.30 | 14.04 | 16.47 |
| Asset Turnover(x) | 1.80 | 1.89 | 1.85 | 0.85 | 0.85 |
| Sales/Fixed Asset(x) | 2.76 | 2.94 | 2.97 | 1.44 | 1.66 |
| Working Capital/Sales(x) | 6.14 | 7.74 | 7.99 | 3.97 | 3.69 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.36 | 0.34 | 0.34 | 0.70 | 0.60 |
| Receivable days | 44.33 | 37.24 | 36.01 | 78.95 | 83.73 |
| Inventory Days | 33.73 | 31.35 | 31.90 | 75.25 | 79.22 |
| Payable days | 191.79 | 191.57 | 219.98 | 218.90 | 226.86 |
| Valuation Parameters | |||||
| PER(x) | 44.14 | 13.25 | 13.51 | 7.49 | 19.69 |
| PCE(x) | 13.27 | 8.43 | 9.27 | 4.87 | 14.56 |
| Price/Book(x) | 1.39 | 1.38 | 1.86 | 0.96 | 3.26 |
| Yield(%) | 0.54 | 0.57 | 0.54 | 1.21 | 0.31 |
| EV/Net Sales(x) | 1.23 | 1.20 | 1.52 | 0.90 | 2.20 |
| EV/Core EBITDA(x) | 6.16 | 5.93 | 7.80 | 5.15 | 12.11 |
| EV/EBIT(x) | 13.14 | 8.47 | 9.60 | 6.50 | 13.29 |
| EV/CE(x) | 0.91 | 0.96 | 1.18 | 0.72 | 1.82 |
| M Cap / Sales | 1.01 | 1.01 | 1.20 | 0.55 | 1.85 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 5.57 | 12.44 | 2.85 | 7.86 | 8.72 |
| Core EBITDA Growth(%) | 4.35 | 16.51 | 14.91 | 3.55 | 5.11 |
| EBIT Growth(%) | -29.97 | 0.22 | 17.80 | -9.90 | 16.39 |
| PAT Growth(%) | -62.02 | 2.43 | 25.02 | -16.11 | 15.07 |
| EPS Growth(%) | -68.44 | -2.92 | 25.01 | -16.11 | 15.08 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.46 | 0.40 | 0.67 | 0.80 | 0.80 |
| Current Ratio(x) | 1.96 | 1.77 | 1.75 | 1.65 | 1.67 |
| Quick Ratio(x) | 1.37 | 1.23 | 1.21 | 1.13 | 1.11 |
| Interest Cover(x) | 3.48 | 5.83 | 4.92 | 3.90 | 4.89 |
| Total Debt/Mcap(x) | 0.33 | 0.29 | 0.36 | 0.84 | 0.24 |
Compare Financial Ratios of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹28,929.7 Cr | 4% | 6.2% | 118% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 4% |
6.2% |
118% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
